Sandoz Raised Its 2024 Net Sales Growth Guidance To High-Single Digits In Constant Currency; Maintains Core EBITDA Margin Guidance At ~20%
Sandoz Raised Its 2024 Net Sales Growth Guidance To High-Single Digits In Constant Currency; Maintains Core EBITDA Margin Guidance At ~20%
Sandoz将其2024年净销售增长预期提高到恒定货币下的高个位数；将核心EBITDA利润率指引保持在约20%
GUIDANCE 2024
2024年导向
On the back of strong momentum in its biosimilars business and solid generics demand, the company is increasing its full-year 2024 net sales guidance to high-single digit growth in constant currencies versus prior year (from mid- to high-single digit) and is confirming its core EBITDA margin guidance of around 20%.
基于生物仿制药业务的强劲动力和稳固的普通需求，该公司将全年2024年度净销售指引提高至固定货币中单位数增长（从中至高个位数），并确认其核心EBITDA利润率指引约为20%。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间